Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanggua Tablets in Impaired Glucose Tolerance and Mild Type 2 Diabetes
NCT06964620Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Herbal Formulation, Combination therapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and impaired glucose tolerance (IGT) comparing Conventional treatment plus Sanggua tablets with Conventional treatment plus placebo (2 arms). Primary endpoint: Hemoglobin A1c at Week 16. Started May 2025; status: recruiting.
02
Drugs
Sanggua
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT06964620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964620.